<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190107042266N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-27</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Extra-amniotic dexamethasone infusion with extra-amniotic salin infusion in cervical ripening for labor induction</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Extra-amniotic dexamethasone infusion with extra-amniotic salin infusion in cervical ripening for labor induction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43805</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: They will randomly be divided into two groups. For randomization, four segmented randomized blocks (permutation) will be used. Will be have two treatment methods. In 4 segmented blocks, two participants will be devoted to intervention group and two participants will be devoted to control group. There will be six different modes for 4 segmented blocks (TTCC, TCTC, TCCT, CCTT, CTCT, CTTC). Designation list will be prepared based on the randomized numbers created by excel with the help of a consultant before initiating the work (between 0 and 1). Rrandomized numbers "0 to 0.16" from the mixture of “TTCC", randomized numbers "0.16 to 0.33" from the mixture of " TCTC", randomized numbers "0.33 to 0.5" from the mixture of “TCCT”, randomized numbers "0.5 to 0.66" from the mixture of "CCTT", randomized numbers "0.66 to 0.83” from the mixture of "CTCT” and randomized numbers “0.83 to 1" from the mixture of "CTTC" will be used, Blinding description: Randomization and allocation will be concealed from the researchers and participants until the final analyses will be completed. Another person at the hospital, who is not involved in the trial and not aware of random sequences, will be assigned the participants into two groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Pregnant wemen.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Foley catheter (size 26) will be inserted into the cervix. The Foley catheter balloon will be filled with 30 ml of sterile water. 20 mg of dexamethasone will be mixed with sterile water to bring the volume to 20 ml. then the Solution will be infused with normal saline sterile infusion (at a rate of 1 ml/min) into the extra amniotic. Every hour after injection، They are examined for exiting  catheter. After exiting  catheter ، Bishop score will be  determined again and labor induction will be implemented with  oxytocin. Intervention 2: Foley catheter (size 26) is inserted into the cervix. The Foley catheter balloon will be filled with 30 ml of sterile water. 20 ml of distilled infused water and then the normal saline sterile infusion will be infused into the exterior amniotic. Every hour after injection، they will be examined for exiting catheter. After exiting catheter ، Bishop score will be determined again and labor induction will be implemented with oxytocin.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is there is not more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Shahrzad Aghaamoo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hospital Amiralmomenin, Mostafa Khomeini Blvd</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514799442</zip>
        <telephone>+98 23 3345 1336</telephone>
        <email>aghaamoo_shahrzad@yahoo.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Shahrzad Aghaamoo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hospital Amir-AlMomenin, Mostafa Khomeini Blvd</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514799442</zip>
        <telephone>+98 23 3345 1336</telephone>
        <email>aghaamoo_shahrzad@yahoo.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gestational age of  37-42 weeks
Candidate for induction of labor
Bishop score of less than 5</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Uterine anomalies
Placenta previa or placental low lying
Authentic History of  vaginal bleeding in the second and third trimester of pregnancy
Active genital herpes
Intrauterine fetal death (IUFD)
History of uterine classic incision
Vasa Previa</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Pregnant s</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Z33</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Foley catheter (size 26) will be inserted into the cervix. The Foley catheter balloon will be filled with 30 ml of sterile water. 20 mg of dexamethasone will be mixed with sterile water to bring the volume to 20 ml. then the Solution will be infused with normal saline sterile infusion (at a rate of 1 ml/min) into the extra amniotic. Every hour after injection، They are examined for exiting  catheter. After exiting  catheter ، Bishop score will be  determined again and labor induction will be implemented with  oxytocin.</i_keyword>
      <i_keyword>Foley catheter (size 26) is inserted into the cervix. The Foley catheter balloon will be filled with 30 ml of sterile water. 20 ml of distilled infused water and then the normal saline sterile infusion will be infused into the exterior amniotic. Every hour after injection، they will be examined for exiting catheter. After exiting catheter ، Bishop score will be determined again and labor induction will be implemented with oxytocin.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cervical ripening. Timepoint: The measurement of cervix at the beginning of the study and before initiation of the intervention (until 6 hours after initiation of the study) till the creation of bishop score of five and higher. Method of measurement: Vaginal exam based on Bishop score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Neonatal Apgar. Timepoint: First and fifth minutes after birth. Method of measurement: Standard method.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-09-16</approval_date>
        <contact_name>Ethics Committee in Semnan University of Medical Sciences</contact_name>
        <contact_address>Semnan University of Medical Sciences, Basij Blvd Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
